This 1983 clinical trial evaluated the effects of oral physostigmine and lecithin on memory in eight patients with early Alzheimer's disease. Six patients showed improvements in total recall and long-term retrieval, with reduced intrusions. Optimal physostigmine doses were 2.0 or 2.5 mg. A double-blind crossover trial confirmed these findings, correlating
